Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B J Cerimele

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Pharmacology|March 20, 1998
Olanzapine: interaction study with imipramineJ T Callaghan, B J Cerimele, K J Kassahun, et al.
British Journal of Clinical Pharmacology|October 1, 1996
Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonistP Marder, S M Spaethe, L L Froelich, et al.
Clinical Pharmacology and Therapeutics|September 1, 1993
Effects of renal dysfunction on the pharmacokinetics of loracarbefD G Therasse, D S Farlow, R L Davidson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapineB J Ring, J Catlow, T J Lindsay, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Clinical Pharmacology|March 20, 1998
Olanzapine: interaction study with imipramineJ T Callaghan, B J Cerimele, K J Kassahun, et al.
British Journal of Clinical Pharmacology|October 1, 1996
Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonistP Marder, S M Spaethe, L L Froelich, et al.
Clinical Pharmacology and Therapeutics|September 1, 1993
Effects of renal dysfunction on the pharmacokinetics of loracarbefD G Therasse, D S Farlow, R L Davidson, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1996
Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapineB J Ring, J Catlow, T J Lindsay, et al.
Pageof 3